Factsheet and Information Brochure
Factsheet
Target Market
Costs and charges
Fund rules (136 kB)
Prospectus (1550 kB)
Periodic reports
Sustainability SFDR (1071 kB)
Annual review (PF) (3188 kB)
Semi-annual report (PF) (186 kB)
Marketing material
Brief fund information
Summary SFDR (168 kB)
Pre-contractual SFDR
Pre-contractual SFDR (1090 kB)
AstraZeneca Allemansfond
Legal name: AstraZeneca Allemansfond
Equity Fund Registered in Sweden (Non-UCITS)
Bid
About risk
Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.
The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca.
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Fund manager
Ulrika Orstadius Experience in the fund industry 2011. Portfolio Manager since 1 November 2022.
|
|
||
|---|---|---|---|
|
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
|
|
31.12.2025
|
||
|---|---|---|---|
|
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating |
|
|
||
|---|---|---|---|
|
This fund promotes environmental and social characteristics through its investments but does not have sustainable investments as its objective. As a result, the fund takes into consideration the environment and climate, as well as human rights, employees’ rights and corruption. The fund is reported as an Article 8 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR). |
|
31.10.2025
|
|||
|---|---|---|---|
|
The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating. The fund complies with the UN Principles for Responsible Investments. |
Graph
Performance
| Rate 06.02.2026 | 1 week | 1 month | 3 months | 2026 | 1 year | 5 years | 10 years |
|---|---|---|---|---|---|---|---|
| 4,497.27 SEK | 3.23% | 2.99% | 6.44% | 2.14% | 6.14% | 96.85% | 283.56% |
Portfolio 26.01.2026
Portfolio manager comments — Q4 2025
The fund delivered positive performance during the period, rising by nearly 11%, although slightly below its benchmark index*.
The largest positive contributions came from AstraZeneca, Volvo, and Sandvik. AstraZeneca reported a strong quarterly result and announced an agreement with the US regarding future drug pricing, which is expected to have a less negative impact than previously anticipated. The early cyclical companies Volvo and Sandvik performed well, with Sandvik benefiting in part from positive order intake within its mining related operations.
The holdings with the most negative impact were Autoliv, Sweco, and Hexagon. Autoliv delivered a quarterly report that exceeded expectations, but guidance for the fourth quarter was weaker than expected. Sweco underperformed in the absence of company specific news, while Hexagon reported weaker than expected results in the business planned to be spun off, Octave.
During the period, exposure to Epiroc was increased following a decline in valuation, while the holding in Sandvik was reduced after strong share price performance. Holdings in Hexagon and Essity were reduced, while exposure was increased to Atlas Copco and Electrolux Professional, where prospects are considered more attractive. The holding in AstraZeneca was also reduced following strong share price performance.
We continue to focus on ensuring that the fund’s companies have sustainable business models and competitive offerings with durable, profitable growth.
* SIX Sweden SRI Index GI (60%), AstraZeneca (40%)
Portfolio distribution 31.12.2025
Geographic breakdown 31.12.2025
